30 May 2024

In March 2024, the EAN published a new guideline on the management of amyotrophic lateral sclerosis (ALS) in the European Journal of Neurology, in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).

This guideline represents a significant update to the EFNS guideline on ALS management, originally published in 2012, and stands as the first EAN guideline on ALS. The development of this guideline took several years, during which our working group had the privilege of collaborating with Cochrane Response for evaluation of the available evidence. Numerous stakeholders contributed to this endeavour, including key opinion leaders from various European nations, systematic reviewers from Cochrane Response, patient representatives from EUpALS, as well as stakeholders from the EAN, ERN EURO-NMD, and ENCALS.

Read the full paper here and check out our infographic below:

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern